Open in interactive viewer → charts, metric popovers & call review

OCSL: The Rate Tide Turned in Its Favor — and the Checkbook Stayed Shut

A 44% cut in non-accruals and a 25bp hike that flows straight to NII, against leverage parked at 1.00x and a stock a quarter below book
OCSL · Earnings Call · 2026-11-17

The sign on the interest line flipped

A year ago this management team was told the Fed would keep cutting. It didn't. Armen Panossian opened the fiscal fourth-quarter call by noting that markets instead got AI-driven volatility, geopolitical shock and renewed inflation — Brent above $100 — and a 25bp hike that took the funds rate to 3.75%–4%, with the 10-year pushing through 5% for the first time in nearly two decades.

A year ago, the debate was how far rates would fall. Today, it is how long they stay high and how high.

Armen Panossian, Chief Investment Officer · 2026-11-17
For a book that is 91% floating rate, that is a revenue event, not a cost event. “Our view is that a move in short-term base rates from approximately 4% to 5% would remain manageable and could be beneficial to investor returns as most of the increase would flow through to net investment income.” — Armen Panossian, Chief Investment Officer · 2026-11-17 Chris McKown put a number on it: “every 25 basis point increase in base rates adds a little over $0.05 per share per quarter” — Christopher McKown, Chief Financial Officer · 2026-11-17 once resets complete — though the transcript's own phrasing then calls that same figure "annualized," which cannot be right; take the nickel-a-quarter as the operative number and the qualitative direction as the real point. This is now the whole market's obsession. The quarter's global keyword board is dominated by rising interest rate environments, the Fed rate hike itself, and the impact of high rates on borrowers. OCSL is on the rare side of that trade — the lender whose income rises while its borrowers absorb the shock. Coverage is 2.3x, and management says a 100bp move takes it to 2.1x, still above the ~1.9x trough the portfolio lived through in late 2023 and early 2024.

The cleanup was earned, not marked

Matt Pendo led with the year's two priorities, and the first one is genuinely done. “non-accruals at fair value have fallen from $81 million a year ago to $45 million today, a reduction of 44%.” — Mathew Pendo, Chief Executive Officer · 2026-11-17 That is 1.8% of the debt portfolio at fair value and 4% at cost, from 6 names versus 10 a year ago. Crucially, roughly 85% of the decline came from proceeds and investments returning to accrual status rather than from write-downs — a distinction that separates a workout shop from a mark-to-model one. The quarter's own resolutions are unusually tidy. BioXcel, added to non-accrual after a Chapter 11, sold its drug to Teva; Teva's FDA approval on November 13 triggered the full $67.5 million milestone, which management expects to be paid within 30 days at a realized value above the carrying mark. Thrasio was fully repaid at par in early November. RumbleOn — marked to 94% back in 2023 — refinanced and repaid $35 million at 101, a year ahead of maturity, after covenant resets bought the company time. And the character of the remaining problems has changed. Raghav Khanna was direct: the 2021–22 wounds were post-COVID normalization layered on capital structures built for 4% base rates, not 5%. The new addition — the largest U.S. opioid treatment center business — broke on bad ERP systems gumming up revenue collection. “when we see problems in the portfolio now, they're idiosyncratic as opposed to because of one big theme.” — Raghav Khanna, Portfolio Manager · 2026-11-17 Software, once the sector's live grenade, is 20% of the portfolio versus 24% a year ago, 94% first lien, with ARR-based loans at 0.8% and high-AI-risk software at roughly 3% of performing debt.

The thesis arrived. The checkbook stayed shut.

Here is the tension worth owning. In August, Panossian said the firm was deliberately holding back: “we are... conserving our capital, maintaining ourselves in a more defensive and risk-averse posture. We really want to be able to lean into the market on the back of what we think will be more volatility.” — Armen Panossian, Chief Investment Officer · 2026-08-05 That volatility came. New sponsor first-lien paper now clears at “SOFR plus 500 to 550 basis points for several months, about 50 to 100 basis points wider than that at the end of 2025” — Armen Panossian, Chief Investment Officer · 2026-11-17, and the direct-lending premium over broadly syndicated loans widened past 150bp. But two things undercut the victory lap. First, spreads have held for months — the repricing stalled at the level Raghav described back in May as already “at least 100 basis points more attractive than they were even 3 months ago” — Raghav Khanna, Co-Chief Investment Officer · 2026-05-05. The window opened and then stopped opening. Second, OCSL barely walked through it: commitments of $179 million versus $206 million the prior quarter and $208 million a year ago, with just $80 million originated in October despite a pipeline building since late September. Net leverage finished at 1.00x, inside a 0.97–1.07x band that never once approached the midpoint of the 0.9–1.25x target that Matt promised a year ago was the plan (“the plan isn't to go to 1.25... the plan is to kind of be at the midpoint of our range” — Mathew M. Pendo, CFO or Head of Finance · 2025-08-05). What did grow was equity: 5.5% of fair value from 3.9%, via three structured, income-producing positions — a quiet admission that the best risk-adjusted returns on offer were not senior loans. One thing a year of analyst questioning did get answered: Moody's moved the outlook to stable in August with Baa3 affirmed, and the company priced $300 million of 5-year notes at 7%, a 240bp spread, or 258bp over SOFR after swapping — inside the cost of the facility it replaces. Liabilities to assets have sat in a 50–55% band for three years and finished the latest period at 51.6%, which is exactly what a company choosing optionality over deployment looks like.

A quarter below book, and no bid from the issuer

The numbers that matter for the equity are less flattering than the credit story. Adjusted NII was $0.34 per share against $0.37, and $1.49 for the year against $1.76. The base dividend was reset in May from $0.40 to $0.30 so that it would be earned rather than borrowed; this quarter's $0.32 total ($0.30 base plus $0.02 supplemental) puts fiscal 2026 dividends at $1.39, or 108% of adjusted NII. NAV slipped to $15.63 from $15.70. Meanwhile the stock sits about 3% lower over ninety days and roughly 11% off its August 31 peak of $13.26, which on the tape's own arithmetic leaves it near $11.80 against that $15.63 book — call it a quarter below NAV. Asked directly about capital allocation, Pendo was candid: “Since we took over management, we have not repurchased shares” — Mathew Pendo, Chief Executive Officer · 2026-11-17, because capital is earmarked for loans. Share repurchases have run about $1 million a quarter — a rounding error against a 25% discount. The share price is not really about OCSL. The private-credit complex has been de-rated all year: the direct lending business basket and the fee related earnings cohort sit among the market's worst 360-day decliners, and anything with a structured, asset-backed wrapper has been sold alongside them. OCSL's drawdown is that discount, applied to a book whose credit marks just improved faster than its income statement could show — the fundamentals file still ends at the June quarter, so none of the fourth-quarter cleanup is in it. The gap between the two stories is the investment case, and also the risk. Management has spent a year saying it would lean in when volatility arrived, and the volatility has arrived with the spread evidence to prove it. What has not arrived is the deployment. Until leverage moves off 1.00x, or the company starts retiring stock a quarter below book, the equity will keep trading the old narrative — credit losses and rate cuts — against a P&L that is now levered to the opposite one.